An interventional study of Support for Caregiver - Generic List and Support for Caregiver - Personalized List in Stage II Lung Cancer, Stage III Lung Cancer and Stage IV Lung Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 25 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 6th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2024, is one of 14 with no phase, and was the 33rd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 50–77
Wake Forest University Health Sciences · Sites in United States
Ages 40–54 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 3
First in 1998; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 31 interventional studies, 55 across the 5 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Lung Neoplasms by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06383988Wake Forest University Health SciencesA Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources | 2026-12-30 |
| NCT07322367Wake Forest University Health SciencesA Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients | 2027-01 |
| NCT07282444Wake Forest University Health SciencesA New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial that tests the feasibility of a web based caregiver support resource, along with caregiver navigation sessions for caregivers of patients with stage II-IV lung cancer. The Caregiver Oncology Needs Evaluation Tool (CONNECT) is a novel web-based intervention designed for the community oncology setting, to systematically connect lung cancer caregivers with tailored supportive care resources. Lung cancer caregivers provide critical and challenging care for their loved ones and are at risk for their own negative psychosocial and physical outcomes. Implementing the CONNECT program along with caregiver navigation may provide additional support to caregivers of patients with stage II-IV lung cancer.
This study is a multi-site randomized pilot trial enrolling 120 lung cancer caregiver-patient dyads (i.e., lung cancer caregivers (n=120) and their care-recipients (n=120)) across approximately 8-12 practices to assess the multi-site feasibility of a caregiver technology-based intervention (CONNECT) to identify caregivers' needs and connect them with supportive care resources. Caregivers will be randomized 1:1:1 to either the CONNECT intervention, usual care comparison group or generic resource list comparison group. CONNECT is a web-based intervention that empowers and educates caregivers about the benefits of supportive care services and systematically identifies unmet needs to connect lung cancer caregivers with tailored supportive care resources. The Central Caregiver Navigator will assist caregivers with resolving barriers to accessing resources and work with the Local Practice Referral Coordinator to process referrals. Caregivers and patients will complete measures at baseline (prior to caregiver randomization), and 12 and 24 weeks after baseline. Feasibility measures (retention, accrual rates, and participation) will be evaluated to inform the future trial. The Local Practice Referral Coordinator for each practice will report on time needed for practice participation, referral processes, and communication processes with the Central Caregiver Navigator.
Participants (i.e., patients or care-recipients) will be asked to complete study surveys at three time points:
Each survey will take about 30-45 minutes to complete. The forms will ask about things such as demographics (sex, race, etc.), cancer symptoms, satisfaction with cancer care and health behaviors. You don't have to answer any question that makes you feel uncomfortable. These surveys can be done remotely over the internet, in the clinic, by phone or by mail.
Caregivers will also complete surveys at three time points and will be assigned to 1 of 3 study groups:
Caregiver Participants (Group 1, 2 and 3) will be asked to complete study surveys at three time points:
Each survey will take about 35-45 minutes to complete. The forms will ask about things such as demographics (sex, race, etc.), caregiving experience, use of supportive care resources, quality of life, mood, and social needs (housing, transportation, utilities, etc). You don't have to answer any question that makes you feel uncomfortable.
Patient Inclusion Criteria:
Caregiver Inclusion Criteria:
Patient Exclusion Criteria:
Caregiver Exclusion Criteria:
Caregivers receive standard care and are then given a generic resource list at week 24.
Other: Support for Caregiver - Generic List
Caregiver receive a generic resource list at the start of the study.
Other: Support for Caregiver - Generic List
Caregivers receive access to the CONNECT tool, watch an educational video on self care and receive a personalized list of resources based on caregiver preferences. Caregivers also receive access to and complete at least 2 calls, at baseline and at week 4, with a caregiver navigator to review the resource list and address any additional needs.
Other: Support for Caregiver - Personalized List · Other: Internet-Based Intervention - CONNECT · Behavioral: Patient Navigation
Receive a generic resource list
Receive personalized resource list
Receive access to CONNECT tool
Complete calls with caregiver navigator
Also known as: Patient Navigator Program
Caregiver retention at 12 weeks
Calculated as the following: Number of caregivers who complete at least 75% of the 12-week assessments divided by the number randomized. Retention will be estimated and reported along with an exact 95% confidence interval.
Time frame: At 12 weeks
Caregiver accrual rate
Number of caregivers who agree to participate divided by the number of months of recruitment
Time frame: Upon completion of recruitment, approximately 12 months
Caregiver participation
Proportion of eligible caregivers who agreed to participate
Time frame: Upon completion of recruitment, approximately 12 months
Caregiver retention at 24 weeks
Number of caregivers who complete at least 75% of the 24-week assessments divided by the number randomized.
Time frame: At 24 weeks
Caregiver acceptability
Self-report survey developed for this study to assess the degree to which caregivers found different aspects of CONNECT, the generic resource list, or usual care helpful using a Likert response from 0 (Not at all) to 5 (Very Much)
Time frame: At 12 weeks
Average time (minutes) needed for training for Local Practice Referral Coordinator
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: At completion of training, up to 6 months
Desired modality for training (e.g., live webinar, recorded video, paper materials) for Local Practice Referral Coordinator
Will be summarized using appropriate descriptive statistics.
Time frame: At completion of training, up to 6 months
Average time (minutes) needed to identify and enter local resources into the Caregiver Oncology Needs Evaluation Tool (CONNECT) database
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: At conclusion of practice intervention activities, an average of 18 months
Frequency of needed resource updates in the CONNECT database
Will be summarized across practices using mean, median, standard deviation and interquartile range
Time frame: Up to completion of practice intervention activities, an average of 18 months
Average time (minutes) spent by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Modality of contact (e.g. phone, virtual web meeting, email) made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm
Will be summarized using appropriate descriptive statistics.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Number of contacts made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Number of referrals facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Type of referrals (e.g., in person, online) facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator
Will be summarized using appropriate descriptive statistics.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Average time (minutes) needed to communicate for Central Caregiver Navigator and Local Practice Referral Coordinator
Will be summarized across practices using mean, median, standard deviation and interquartile range.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Modalities used for communication (e.g., phone, virtual web meeting, email) for Central Caregiver Navigator and Local Practice Referral Coordinator
Will be summarized using appropriate descriptive statistics.
Time frame: Up to completion of practice intervention activities, an average of 18 months
Improvements for the future trial from Local Practice Referral Coordinator's perspectives from a survey at the end of the study
Will be summarized using appropriate descriptive statistics.
Time frame: At completion of practice intervention activities, an average of 18 months
Patient accrual rate
Number of patients who agree to participate divided by the number of months of recruitment
Time frame: Upon completion of recruitment, approximately 12 months
Patient participation rate
Proportion of eligible patients who agreed to participate
Time frame: Upon completion of recruitment, approximately 12 months
Patient retention at 12 weeks
Number of patients who complete at least 75% of the 12-week assessments divided by the number randomized
Time frame: At 12 weeks
Patient retention at 24 weeks
Number of patients who complete at least 75% of the 24-week assessments divided by the number randomized
Time frame: At 24 weeks
Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.
Time frame: 6 months after publication for a 2 year duration
Access criteria: upon request to NCORP@wakehealth.edu
Data sharing details ↗ · nctn-data-archive.nci.nih.gov
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 25 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →